Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LON002 Extension Study in Solid Tumors
NCT02390986Unknown
- Start
- Jan 2015
- Primary completion
- Jun 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of artemether in solid tumor. Primary endpoints: Proportion of patients with Adverse Events grade ≥3 related to LON002 at 6 months and Proportion of patients with Serious Adverse Events related to LON002 at 6 months. Status: unknown.
02
Drugs
artemether
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02390986.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02390986.